Skip to content
Kobo Biotech logo

Kobo Biotech

531541 BSE
Price unavailable

Kobo Biotech (KOBO) share price was ₹3.94 at the 28 Oct 2026 close; market capitalisation ₹9.40 Cr; sector Chemicals. The share price rose 15.5% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2024 quarter, revenue was under ₹1 Cr in both quarters and net profit was −₹1.33 Cr, against −₹1.23 Cr a year earlier (compared with Jun 2023). Promoters held 44.95% of Kobo Biotech in Jun 2026, unchanged from Mar 2026.

Close 28 Oct 2026 ₹3.94 +0.50 +14.53% 1Y

Key Fundamentals

MicrocapChemicals & PetrochemicalsChemicals
Market Cap
₹9.40 Cr
EBITDA
−₹70.00 L
Return on Equity
-65.6%
Debt to Equity
3.38
Book Value
−₹57.98
EPS (TTM)
−₹2.10
52W High
₹9.99
52W Low
₹1.99

Price-based figures as of 28 Oct 2026, 15:30 IST · TTM

Peer Comparison

Commodities › Chemicals › Commodity Chemicals

SRF
₹2,350.0032.2269,660 Cr4.550.21%13.07%14.64%17,997 Cr2,162 Cr
Tata Chemicals
₹604.60—15,403 Cr0.731.84%-7.73%-2.69%15,521 Cr-1,971 Cr
Deepak Fertilisers & Petrochemicals
₹1,178.1015.1114,872 Cr2.170.84%9.90%11.30%12,189 Cr984 Cr
Gujarat Narmada Valley Fert & Chem
₹515.207.307,570 Cr0.834.12%8.75%10.38%8,860 Cr1,037 Cr
Tanfac Industries
—103.797,489 Cr10.360.13%18.80%25.38%725 Cr68 Cr
Gujarat Alkalies & Chemicals
₹552.7561.144,060 Cr0.783.20%-0.05%1.29%4,622 Cr66 Cr
GHCL
₹387.407.713,569 Cr1.003.04%13.30%16.87%3,138 Cr473 Cr
Kobo Biotech (this company)
——9 Cr—0.00%-65.60%-7.79%0 Cr-5 Cr
Median 8 companies₹578.6823.677,529 Cr1.001.34%9.33%10.84%6,741 Cr271 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

—

Insufficient data

Not enough numeric coverage across the required pillars to publish a Tapetide Score for this stock.

Coverage 52%

Key Insights

Weaknesses

1
  • Company has low interest coverage ratio.

Technical Indicators

Oscillators

Bullish

Bearish
1
Neutral
3
Bullish
5

Overall

Bearish

Bearish
11
Neutral
3
Bullish
5

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
—

Net Income Growth
-6% lower than 3Y

change over 1 year

Cash Flow Change
117%

change over 1 year

EBITDA Margin Change
—

Quarterly Results

Particulars Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Sales
0
0
0
0
0
0
0
0
0
0
0
0
0
Expenses
0.27
0.7
0.3
9.24
0.34
0.21
0.17
0.79
0.23
0.2
0.2
0.25
0.34
Operating Profit
-0.27
-0.7
-0.3
-9.24
-0.34
-0.21
-0.17
-0.79
-0.23
-0.2
-0.2
-0.25
-0.34
Other Income
0.02
0
0
0
0.02
0
0
0
0.02
0
0
0
0.02
Interest
0
0.13
0
0
0
0
0
0
0
0
0
0
0
Depreciation
1.35
1.03
1.04
1.18
1.15
0.89
1.03
1
1.01
1.02
1.03
1.01
1.01
PBT
-1.6
-1.86
-1.34
-10.42
-1.47
-1.1
-1.2
-1.79
-1.22
-1.22
-1.23
-1.26
-1.33
Tax %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Net Profit
-1.6
-1.86
-1.35
-10.42
-1.47
-1.1
-1.19
-1.79
-1.23
-1.22
-1.23
-1.26
-1.33
EPS (₹)
-0.67
-0.78
-0.57
-4.37
-0.62
-0.46
-0.5
-0.75
-0.52
-0.51
-0.52
-0.53
-0.56
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Sales
56.89
29.05
32.54
0
0
0
0
0
0
0
0
0
Expenses
61.34
38.51
27.74
4.05
3.02
1.72
0.69
2.79
10.51
1.5
0.88
1.24
Operating Profit
-4.45
-9.46
4.8
-4.05
-3.02
-1.72
-0.69
-2.79
-10.51
-1.5
-0.88
-1.24
OPM %
-7.82%
-32.56%
14.75%
—
—
—
—
—
—
—
—
—
Other Income
0.18
2.6
0.42
6
0.04
-2.15
0.03
0.04
0.02
0.02
0.02
0.08
Interest
18.14
15.62
14.37
14.41
14.5
14.44
14.47
10.84
0.13
0
0
0
Depreciation
9.62
7.78
7.31
6.78
6.44
6.15
5.88
5.64
4.61
4.07
4.07
4.07
PBT
-32.03
-30.26
-16.46
-19.24
-23.92
-24.46
-21.01
-19.23
-15.23
-5.55
-4.93
-5.23
Tax %
1.69%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Net Profit
-32.57
-30.26
-16.46
-19.24
-23.92
-24.46
-21.01
-19.23
-15.23
-5.55
-4.93
-5.23
EPS (₹)
-14.48
-13.45
-6.94
-8.08
-10.04
-10.27
-8.82
-8.07
-6.39
-2.33
-2.07
-2.2
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital
22.5
22.5
23.73
23.83
23.83
23.83
23.83
23.83
23.83
23.83
23.83
23.83
Reserves
22.07
-8.83
-17.3
-42.41
-66.33
-90.79
-112
-131
-146
-152
-157
-162
Borrowings
137
142
153
208
222
236
251
261
141
140
140
140
Other Liabilities
97.45
95.74
101
63.2
66.48
70.04
73.54
77.26
60.89
63.47
64.62
70.04
Total Liabilities
279
252
260
252
246
239
236
231
79.18
75.33
71.4
71.59
Fixed Assets
104
95.1
87.79
81.01
74.56
68.42
62.54
56.91
41.66
37.59
33.52
29.44
CWIP
2.25
2.25
2.25
2.25
2.25
2.25
2.25
2.25
0
0
0
0
Investments
12.19
12.19
12.19
12.19
12.19
12.19
12.19
12.19
0
0
0
0
Other Assets
161
142
158
157
157
157
159
159
37.52
37.74
37.88
42.15
Total Assets
279
252
260
252
246
239
236
231
79.18
75.33
71.4
71.59
Figures in ₹ Crores

Cash Flow

Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating
11.02
19.32
5.62
32.3
31.47
20.95
14.48
2.51
93.76
0.87
0.2
4.18
Investing
-4.71
0
0
0
0
0
0
0
25.09
0
0
0
Financing
-7
-20.5
-5.27
-32.76
-31.47
-20.95
-14.47
-1.08
-120
-0.87
-0.15
0
Net Cash Flow
-0.69
-1.18
0.35
-0.46
0
0
0
1.43
-1.43
0
0.05
4.18
Free Cash Flow
6.31
19.32
5.62
32.3
31.47
20.95
14.48
2.51
107
0.87
0.2
4.18
CFO/OP
-260
-204
117
-798
-1,042
-1,218
-2,099
-90
-892
-58
-23
-337
Figures in ₹ Crores

Ratios

Particulars Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
419
706
1,007
—
—
—
—
—
—
—
—
—
Inventory Days
585
896
1,039
—
—
—
—
—
—
—
—
—
Days Payable
405
660
1,093
—
—
—
—
—
—
—
—
—
Cash Conversion Cycle
599
943
953
—
—
—
—
—
—
—
—
—
Working Capital Days
26.63
-277
-251
—
—
—
—
—
—
—
—
—
ROCE %
-7.12%
-10.18%
-1.33%
-2.77%
-5.11%
-4.49%
-3.94%
-5.31%
-17.6%
-36.82%
-52.9%
-125.57%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Kobo Biotech insights

60 extracted metrics + investor summaries across FY08–FY25.

Shareholding Pattern

Public45.72%Others9.33%Promot.44.95%As ofJun 2026

Documents

Frequently Asked Questions about Kobo Biotech

What does Kobo Biotech Ltd do?
Incorporated in 1993, Kobo Biotech Ltd is in the pharmaceutical business[1]
Where is Kobo Biotech Ltd (KOBO) listed?
Kobo Biotech Ltd trades under code 531541 on the BSE.
Which sector does Kobo Biotech Ltd belong to?
Kobo Biotech Ltd is classified under the Chemicals sector, in the Commodity Chemicals industry.
What is the market capitalisation of Kobo Biotech Ltd?
Kobo Biotech Ltd has a market capitalisation of ₹9.4 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Kobo Biotech Ltd?
Over the last 52 weeks Kobo Biotech Ltd has traded between ₹1.99 and ₹9.99 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Kobo Biotech Ltd?
Kobo Biotech Ltd reported a return on equity of -65.60%. Its debt-to-equity ratio is 3.38.

Company Information

Incorporated in 1993, Kobo Biotech Ltd is in the pharmaceutical business[1]

Website avonlifesciences.com
Face Value ₹ 10
Shares Outstanding 2,38,66,348

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531541.md for Kobo Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Chemical & Petrochemical stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month